First Swiss Patients Treated with the Percutaneous MitraClip(R) System
Use of the MitraClip(R) System Continues to Expand in the European Union
Mitral regurgitation is the most common type of heart valve insufficiency in
The first patients in
“Until now, many heart failure patients with associated functional MR had no therapeutic options except medical management when surgery was not possible either because they have already had heart surgery, or presented with important renal insufficiency or lung disease, all of which significantly increase the risk of a second or a third operation,” said Prof. Moccetti, Head of Cardiology Division and Medical Director of Cardiocentro Ticino. He added “The MitraClip(R) therapy provides a valuable alternative for these patients.”
Professor Auricchio, Director of the Heart Failure Clinic commented: “Heart failure is a devastating disease, significantly more common than cancer and has the same poor life-expectancy. Implantable devices such as cardiac resynchronization therapy have improved the quality of life of these patients. Now with percutaneous mitral valve repair, I am confident we can expand our treatment possibilities to many of our Swiss heart failure patients.”
Evalve initiated commercial sales of the MitraClip(R) system in
“We are very pleased to see the successful initial use of the MitraClip device in
About the MitraClip(R) Procedure
Percutaneous mitral repair with Evalve’s MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.
About Evalve, Inc.
Founded in 1999, Evalve, Inc., headquartered in
The MitraClip(R) system is currently undergoing clinical evaluation in
MitraClip(R) and Evalve are registered trademarks of Evalve, Inc.
SOURCE Evalve, Inc.